The Agenus (NASDAQ:AGEN) saga just keeps getting more interesting with the twists and turns reaching back through time. My first article on the company back in August chronicles its history twenty years back, with special focus on Prophage, then called Oncophage, the company's heat shock protein [HSP] cancer vaccine platform. As a quick review, Prophage makes use of HSP's as an "antigen mold," so to speak, which allows immune cells called dendritic cells to pick up the antigens of a tumor from those HSP proteins which fold themselves around the tumor antigens.
Back in 2002, Agenus initiated a high profile phase 3 study of Prophage for melanoma. It failed miserably, not because Prophage failed to meet any endpoints,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|